- $36.58bn
- $40.42bn
- $10.40bn
Alcon shares seen rising after outlook hike
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
Swiss stocks - Factors to watch on August 11
Alcon lifts 2026 outlook after Q2 adjusted EPS beat estimates
Swiss stocks - Factors to watch on July 7
Swiss eye care firm Alcon's quarterly revenue rises less than expected (updated)
Swiss eye care firm Alcon's quarterly revenue rises, driven by product launches
Swiss stocks - Factors to watch on May 6
Switzerland's Alcon Q1 adjusted EPS beats estimates; ups FY profit view
Brief: Alcon Q1 Core Operating Margin 21.2%
Swiss stocks - Factors to watch on May 5
Swiss stocks - Factors to watch on April 30
Brief: Alcon Publishes Agenda For 2026 Annual General Meeting
FTC monitoring how drug companies react to patent cliff, official says
Brief: US FTC Says It Stops Proposed Merger Of Cataract-Surgery Device Makers Lensar And Alcon
US FDA declines to approve Aldeyra's eye disorder drug, shares slump (updated)
US FDA declines to approve Aldeyra's drug for eye disorder
Swiss stocks - Factors to watch on March 17
Brief: Alcon And Lensar Agree To Terminate Merger Agreement